Gabapentin
- Generic Name
- Gabapentin
- Brand Names
- Gralise, Neurontin
- Drug Type
- Small Molecule
- Chemical Formula
- C9H17NO2
- CAS Number
- 60142-96-3
- Unique Ingredient Identifier
- 6CW7F3G59X
- Background
Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) that was first approved for use in the United States in 1993. It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures - today it is also widely used to treat neuropathic pain. Gabapentin has some stark advantages ...
- Indication
In the United States, gabapentin is officially indicated for the treatment of postherpetic neuralgia in adults and for the adjunctive treatment of partial-onset seizures, with or without secondary generalization, in patients 3 years of age and older. In Europe, gabapentin is indicated for adjunctive therapy in the treatment of partial-onset seizures, with or...
- Associated Conditions
- Partial-Onset Seizures, Peripheral Neuropathic Pain, Postherpetic Neuralgia
- Associated Therapies
- -
Study of Neuroimaging Biomarkers of Social Cognition Deficits in Adolescents (Age 13-17) With Autism Spectrum Disorder and Effects of Gabapentin
- First Posted Date
- 2018-07-18
- Last Posted Date
- 2022-11-02
- Lead Sponsor
- University of Massachusetts, Worcester
- Target Recruit Count
- 19
- Registration Number
- NCT03589898
- Locations
- 🇺🇸
University of Massachusetts Medical School, Worcester, Massachusetts, United States
Use of Preoperative Gabapentin in Patients Undergoing Laparoscopic Cholecystectomy
- Conditions
- Interventions
- First Posted Date
- 2018-07-12
- Last Posted Date
- 2019-08-09
- Lead Sponsor
- Centro Hospitalar do Porto
- Target Recruit Count
- 60
- Registration Number
- NCT03583892
- Locations
- 🇵🇹
Centro Hospitalar do Porto, Porto, Portugal
Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy
- Conditions
- Interventions
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2021-12-09
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 62
- Registration Number
- NCT03574792
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Opioid-Free Shoulder Arthroplasty
- Conditions
- Interventions
- First Posted Date
- 2018-05-30
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- OrthoCarolina Research Institute, Inc.
- Target Recruit Count
- 86
- Registration Number
- NCT03540030
- Locations
- 🇺🇸
OrthoCarolina Research Institute, Charlotte, North Carolina, United States
Multimodal Analgesia Versus Traditional Opiate Based Analgesia
- Conditions
- Interventions
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 225
- Registration Number
- NCT03521167
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Conditions
- Interventions
- Drug: Tranexamic acid (TXA)Drug: HydrocodoneDrug: labetalolDrug: metforminDrug: nifedipineDrug: oxycodoneDrug: clindamycinDrug: azithromycinDrug: escitalopramDrug: sertralineDrug: CiprofloxacinDrug: ondansetronDrug: DoxycyclineDrug: LevofloxacinDrug: MethylphenidateDrug: CitalopramDrug: SumatriptanDrug: CyclobenzaprineDrug: FurosemideDrug: RosuvastatinDrug: GabapentinDrug: HydrochlorothiazideDrug: HydroxyureaDrug: TrazodoneDrug: TopiramateDrug: ValganciclovirDrug: RemdesivirDrug: VenlafaxineDrug: VerapamilDrug: FluvoxamineDrug: AnakinraDrug: TocilizumabDrug: AmoxicillinDrug: BupropionDrug: BuprenorphineDrug: LevetiracetamDrug: ParoxetineDrug: Duloxetine
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Duke University
- Target Recruit Count
- 1600
- Registration Number
- NCT03511118
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Loma Linda University Health, Loma Linda, California, United States
A Prospective Randomized Double Blind Trial to Assess the Effect of a Single Preoperative Dose of Gabapentin on Postoperative Opioid Consumption in Patients Undergoing Rhinoplasty
- Conditions
- Interventions
- First Posted Date
- 2018-04-13
- Last Posted Date
- 2023-04-26
- Lead Sponsor
- Ohio State University
- Target Recruit Count
- 50
- Registration Number
- NCT03498261
- Locations
- 🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Does Gabapentin Reduce Quadriceps Muscle Weakness After Anterior Cruciate Ligament Reconstruction?
- Conditions
- Interventions
- First Posted Date
- 2018-04-12
- Last Posted Date
- 2018-04-12
- Lead Sponsor
- Hospital Authority, Hong Kong
- Target Recruit Count
- 30
- Registration Number
- NCT03496389
Bariatric Surgery and Pharmacokinetics of Gabapentin
- Conditions
- First Posted Date
- 2018-03-26
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Norwegian University of Science and Technology
- Target Recruit Count
- 12
- Registration Number
- NCT03476538
- Locations
- 🇳🇴
St. Olavs University Hospital, Trondheim, Norway
MAST Trial: Multi-modal Analgesic Strategies in Trauma
- First Posted Date
- 2018-03-21
- Last Posted Date
- 2021-06-18
- Target Recruit Count
- 1561
- Registration Number
- NCT03472469
- Locations
- 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.